AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22808955 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical prostatectomy
Number of subjects: 731
Study 22808955 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 731
Study 20523080 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency left (HFL) rTMS
Number of subjects: 74
Study 20523080 — intervention group
Group type: COMPARATOR
Intervention: Low-frequency right (LFR) rTMS
Number of subjects: 74
Study 20523080 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole sample
Number of subjects: 74
Study 18270575 — intervention group
Group type: EXPERIMENTAL
Intervention: HAMS‐ORS (hypo‐osmolar ORS with amylase resistant high amylose maize starch 50g/L)
Number of subjects: 50
Study 18270575 — intervention group
Group type: COMPARATOR
Intervention: HO‐ORS (hypo‐osmolar ORS)
Number of subjects: 50
Study 18270575 — intervention group
Group type: EXPERIMENTAL
Intervention: HAMS‐ORS
Number of subjects: 50
Study 18270575 — intervention group
Group type: COMPARATOR
Intervention: HO‐ORS
Number of subjects: 50
Study 15743422 — intervention group
Group type: EXPERIMENTAL
Intervention: Emdogain Gel (EMDgel)
Number of subjects: 18
Study 15743422 — intervention group
Group type: COMPARATOR
Intervention: Calcium hydroxide and sterile saline
Number of subjects: 18
Study 14692305 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone 5 mg/day
Number of subjects: 30
Study 14692305 — intervention group
Group type: COMPARATOR
Intervention: ECE/MPA (equine conjugated estrogens 0.625 mg + medroxyprogesterone acetate 2.5 mg/day)
Number of subjects: 30
Study 14692305 — intervention group
Group type: COMPARATOR
Intervention: ECE/MPA
Number of subjects: 30
Study 10820349 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% 5-aminolevulinic acid (5-ALA) topical application after 60-90 minutes
Number of subjects: 68
Study 10820349 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorescence spectroscopy after 60-90 minutes
Number of subjects: 68
Study 10820349 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% 5-ALA
Number of subjects: 68
Study 8014326 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 126
Study 8014326 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 126
Study 8014326 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study 2685655 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinemet CR
Number of subjects: 0
Study 2685655 — intervention group
Group type: COMPARATOR
Intervention: Standard Sinemet
Number of subjects: 0
Study 781882 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillin (20 mega-units daily)
Number of subjects: 52
Study 781882 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 30407276 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT (135 mL of RBC)
Number of subjects: 9
Study 30407276 — intervention group
Group type: COMPARATOR
Intervention: Sham transfusion (PLA)
Number of subjects: 9
Study 30407276 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT (combined 135 mL and 235 mL of RBC)
Number of subjects: 9
Study 28623895 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise therapy (Ex group: 18 subjects) - brisk walking for 30 min per day for 12 months
Number of subjects: 36
Study 28623895 — intervention group
Group type: COMPARATOR
Intervention: Control group (C group: 18 subjects) - no exercise therapy guidance, only recorded daily steps
Number of subjects: 36
Study 25631224 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly regular didactic lecture (Group 2)
Number of subjects: 360
Study 25631224 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly interactive education workshop (Group 3)
Number of subjects: 360
Study 25631224 — intervention group
Group type: COMPARATOR
Intervention: Self-learning reading (Group 1)
Number of subjects: 360
Study 25631224 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 360
Study 25631224 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 3
Number of subjects: 360
Study 23711100 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 0
Study 23711100 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 0
Study 20527302 — intervention group
Group type: EXPERIMENTAL
Intervention: Two tests separated by interpolated tasks
Number of subjects: 0
Study 20527302 — intervention group
Group type: EXPERIMENTAL
Intervention: Two tests
Number of subjects: 0
Study 20527302 — intervention group
Group type: COMPARATOR
Intervention: One test (control)
Number of subjects: 0
Study 18280581 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant
Number of subjects: 100
Study 18280581 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 16634995 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosinopril 20 mg daily
Number of subjects: 38
Study 16634995 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 12785242 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive training of sit-to-stand and step-up exercises for four weeks
Number of subjects: 24
Study 12785242 — intervention group
Group type: COMPARATOR
Intervention: Usual rehabilitation programme without additional training
Number of subjects: 24
Study 12785242 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group
Number of subjects: 24
Study 12785242 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 24
Study 10962547 — intervention group
Group type: COMPARATOR
Intervention: High dose methylprednisolone (HD MP)
Number of subjects: 0
Study 9169953 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg/day beta-carotene in enteral feeding
Number of subjects: 26
Study 9169953 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 9169953 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (beta-carotene and placebo)
Number of subjects: 26
Study 1494580 — intervention group
Group type: EXPERIMENTAL
Intervention: VRP 1 physiotherapy
Number of subjects: 20
Study 1494580 — intervention group
Group type: COMPARATOR
Intervention: Autogenic drainage (AD)
Number of subjects: 20
Study 3992070 — intervention group
Group type: EXPERIMENTAL
Intervention: Hay fever treatments (specific treatments not detailed)
Number of subjects: 0
Study 30111213 — intervention group
Group type: EXPERIMENTAL
Intervention: Music intervention
Number of subjects: 28
Study 30111213 — intervention group
Group type: COMPARATOR
Intervention: Control group (no music intervention)
Number of subjects: 28
Study 29265566 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of ropivacaine 0.2%
Number of subjects: 120
Study 29265566 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent bolus of ropivacaine 0.2%
Number of subjects: 120
Study 26067286 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional medical treatment plus respiratory physiotherapy for 3 weeks
Number of subjects: 54
Study 26067286 — intervention group
Group type: COMPARATOR
Intervention: Conventional medical treatment
Number of subjects: 54
Study 25209122 — intervention group
Group type: COMPARATOR
Intervention: Mitchell's osteotomy (MO)
Number of subjects: 120
Study 25209122 — intervention group
Group type: EXPERIMENTAL
Intervention: Chevron osteotomy (CO)
Number of subjects: 120
Study 22554359 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 80 mg
Number of subjects: 55
Study 22554359 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 20602884 — intervention group
Group type: EXPERIMENTAL
Intervention: Shikani Optical Stylet (SOS) laryngoscope
Number of subjects: 41
Study 20602884 — intervention group
Group type: COMPARATOR
Intervention: Macintosh direct laryngoscope (MDLS)
Number of subjects: 41
Study 18076237 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent aerobic exercise (1:1 minute at V(.‐)O2max)
Number of subjects: 8
Study 18076237 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous aerobic exercise (90% of the anaerobic threshold velocity)
Number of subjects: 8
Study 18076237 — intervention group
Group type: COMPARATOR
Intervention: Control (rested state strength tests)
Number of subjects: 8
Study 16250910 — intervention group
Group type: EXPERIMENTAL
Intervention: Offering study results in a postal questionnaire (788 participants)
Number of subjects: 1038
Study 16250910 — intervention group
Group type: COMPARATOR
Intervention: Not offering study results in a postal questionnaire (250 participants)
Number of subjects: 1038
Study 12386351 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterine balloon therapy (UBT)
Number of subjects: 255
Study 12386351 — intervention group
Group type: EXPERIMENTAL
Intervention: Rollerball ablation
Number of subjects: 255
Study 12386351 — intervention group
Group type: EXPERIMENTAL
Intervention: Total population (255 women)
Number of subjects: 255
Study 9918905 — intervention group
Group type: EXPERIMENTAL
Intervention: Tauroursodeoxycholate (750 mg/d for 2 months)
Number of subjects: 12
Study 9918905 — intervention group
Group type: COMPARATOR
Intervention: Ursodeoxycholate (750 mg/d for 2 months)
Number of subjects: 12
Study 7669308 — intervention group
Group type: EXPERIMENTAL
Intervention: Cricoid pressure application
Number of subjects: 50
Study 7669308 — intervention group
Group type: COMPARATOR
Intervention: Control (no cricoid pressure)
Number of subjects: 50
Study 1859038 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine sulfate in saline (AS/S) nasal spray
Number of subjects: 90
Study 1859038 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 90
Study 6885408 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback
Number of subjects: 24
Study 6885408 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Psychotherapy
Number of subjects: 24
Study 6885408 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback plus Brief Psychotherapy
Number of subjects: 24
Study 6885408 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list Control
Number of subjects: 24
Study 31619181 — intervention group
Group type: EXPERIMENTAL
Intervention: SCC-BMS (ultrathin strut silicon-carbide coated cobalt-chromium bare-metal stent)
Number of subjects: 1526
Study 31619181 — intervention group
Group type: COMPARATOR
Intervention: UC-BMS (older thin-strut uncoated cobalt-chromium bare-metal stent)
Number of subjects: 1526
Study 31619181 — intervention group
Group type: EXPERIMENTAL
Intervention: SCC-BMS
Number of subjects: 1526
Study 31619181 — intervention group
Group type: COMPARATOR
Intervention: UC-BMS
Number of subjects: 1526
Study 30567604 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured and monitored Nutrition + Exercise intervention
Number of subjects: 242
Study 30567604 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 242
Study 26992740 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure (PE) delivered via home-based telemedicine (HBT)
Number of subjects: 0
Study 26992740 — intervention group
Group type: COMPARATOR
Intervention: Prolonged Exposure (PE) delivered in-person
Number of subjects: 0
Study 25211927 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy including local negative pressure and laser illumination (LLNP)
Number of subjects: 62
Study 25211927 — intervention group
Group type: EXPERIMENTAL
Intervention: Monotherapy with LLNP
Number of subjects: 62
Study 25211927 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 62
Study 25211927 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of LLNP with PDE5 inhibitors
Number of subjects: 62
Study 25211927 — intervention group
Group type: EXPERIMENTAL
Intervention: LLNP methodology
Number of subjects: 62
Study 25211927 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-therapy
Number of subjects: 62
Study 23187979 — intervention group
Group type: EXPERIMENTAL
Intervention: Short motivational interview, barrier reduction, outpatient appointment established, reminders before scheduled appointment
Number of subjects: 24
Study 23187979 — intervention group
Group type: COMPARATOR
Intervention: Standard referral (telephone number for a mental health provider)
Number of subjects: 24
Study 20568934 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical arthroplasty
Number of subjects: 24
Study 20568934 — intervention group
Group type: COMPARATOR
Intervention: Anterior cervical discectomy and fusion (control)
Number of subjects: 24
Study 20568934 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar arthroplasty
Number of subjects: 24
Study 20568934 — intervention group
Group type: COMPARATOR
Intervention: Anterior lumbar interbody fusion (control)
Number of subjects: 24
Study 18028739 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly purified human menopausal gonadotrophin (HP‐HMG)
Number of subjects: 731
Study 18028739 — intervention group
Group type: COMPARATOR
Intervention: Recombinant FSH (rFSH)
Number of subjects: 731
Study 18028739 — intervention group
Group type: EXPERIMENTAL
Intervention: HP‐HMG
Number of subjects: 731
Study 18028739 — intervention group
Group type: COMPARATOR
Intervention: rFSH
Number of subjects: 731
Study 16059716 — intervention group
Group type: EXPERIMENTAL
Intervention: Updated GHb levels
Number of subjects: 3539
Study 16059716 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting plasma glucose levels
Number of subjects: 3539
Study 12198700 — intervention group
Group type: EXPERIMENTAL
Intervention: Variceal band ligation (VBL)
Number of subjects: 172
Study 12198700 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (PPL)
Number of subjects: 172
Study 12198700 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide-5-mononitrate (ISMN)
Number of subjects: 172
Study 9925136 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus acidophilus BG2FO4, ingested twice per day for 7 days
Number of subjects: 42
Study 9925136 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-omeprazole-treated)
Number of subjects: 42
Study 8583783 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide (ANP) infusion (48 pmol/kg/min for 15 min)
Number of subjects: 13
Study 8583783 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 13
Study 2197347 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous penicillin
Number of subjects: 40
Study 2197347 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 40
Study 510213 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin (20 mg/d)
Number of subjects: 14
Study 510213 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 30992113 — intervention group
Group type: EXPERIMENTAL
Intervention: BD, ZOE, SSC
Number of subjects: 40
Study 30992113 — intervention group
Group type: EXPERIMENTAL
Intervention: BD, RMGIC, SSC
Number of subjects: 40
Study 30992113 — intervention group
Group type: EXPERIMENTAL
Intervention: BD, SSC
Number of subjects: 40
Study 30992113 — intervention group
Group type: COMPARATOR
Intervention: BD only (control)
Number of subjects: 40
Study 27712970 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical model for protamine titration
Number of subjects: 60
Study 27712970 — intervention group
Group type: COMPARATOR
Intervention: Fixed protamine‐heparin dose ratio (1:1)
Number of subjects: 60
Study 25779948 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) with tigatuzumab
Number of subjects: 52
Study 25779948 — intervention group
Group type: COMPARATOR
Intervention: Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) without tigatuzumab
Number of subjects: 52
Study 25779948 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of CTC cluster
Number of subjects: 52
Study 23973144 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular exercise (average duration 12 weeks)
Number of subjects: 113
Study 23973144 — intervention group
Group type: EXPERIMENTAL
Intervention: Total joint replacement surgery (3 months post-surgery)
Number of subjects: 113
Study 23973144 — intervention group
Group type: COMPARATOR
Intervention: Matched controls (n = 43)
Number of subjects: 113
Study 22143911 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus
Number of subjects: 380
Study 19064977 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring for lack of benefit in randomized clinical trials
Number of subjects: 0
Study 19064977 — intervention group
Group type: COMPARATOR
Intervention: Commonly used monitoring guidelines
Number of subjects: 0
Study 17845379 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition knowledge intervention (details not specified)
Number of subjects: 177
Study 17845379 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest 10% of nutrition knowledge score
Number of subjects: 177
Study 17845379 — intervention group
Group type: COMPARATOR
Intervention: General population of older adults
Number of subjects: 177
Study 14981605 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (10 mg/d orally)
Number of subjects: 33
Study 14981605 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 11180005 — intervention group
Group type: EXPERIMENTAL
Intervention: Suberythemal dose of whole body irradiation from ultraviolet-A-emitting fluorescent tubes
Number of subjects: 7
Study 11180005 — intervention group
Group type: COMPARATOR
Intervention: Matched control group of unirradiated individuals
Number of subjects: 7
Study 9589815 — intervention group
Group type: EXPERIMENTAL
Intervention: Foscarnet (four doses)
Number of subjects: 12
Study 9589815 — intervention group
Group type: EXPERIMENTAL
Intervention: Zalcitabine (five doses)
Number of subjects: 12
Study 9589815 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant foscarnet (four doses) and zalcitabine (six doses)
Number of subjects: 12
Study 7920609 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse cyclophosphamide (0.5‐1.0 g/m2 body surface area) for 4 months, followed by bimonthly doses for 4 months and quarterly doses for 6 months
Number of subjects: 29
Study 7920609 — intervention group
Group type: COMPARATOR
Intervention: Pulse methylprednisolone (10‐20 mg/kg weight) initially for 3 consecutive days and thereafter in the same intervals as cyclophosphamide
Number of subjects: 29
Study 3279351 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 micrograms Cabergoline
Number of subjects: 32
Study 3279351 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 micrograms Cabergoline
Number of subjects: 32
Study 3279351 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 micrograms Cabergoline
Number of subjects: 32
Study 3279351 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 29356864 — intervention group
Group type: EXPERIMENTAL
Intervention: Lure task (lures, targets, and neutral events presented)
Number of subjects: 126
Study 29356864 — intervention group
Group type: COMPARATOR
Intervention: Standard task (targets and neutral events only)
Number of subjects: 126
Study 26364953 — intervention group
Group type: EXPERIMENTAL
Intervention: Bonemaster (BM)
Number of subjects: 55
Study 26364953 — intervention group
Group type: COMPARATOR
Intervention: Conventional plasma-sprayed hydroxyapatite (HA)
Number of subjects: 55
Study 23994192 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS (2mA, 30-min, 10-daily sessions and two additional fortnight sessions)
Number of subjects: 102
Study 23994192 — intervention group
Group type: COMPARATOR
Intervention: Placebo sertraline
Number of subjects: 102
Study 23731168 — intervention group
Group type: EXPERIMENTAL
Intervention: Silodosin (8 mg/day, n=53)
Number of subjects: 97
Study 23731168 — intervention group
Group type: COMPARATOR
Intervention: Naftopidil (75 mg/day, n=44)
Number of subjects: 97
Study 23731168 — intervention group
Group type: EXPERIMENTAL
Intervention: Silodosin (8 mg/day)
Number of subjects: 97
Study 23731168 — intervention group
Group type: COMPARATOR
Intervention: Naftopidil (75 mg/day)
Number of subjects: 97
Study 19996137 — intervention group
Group type: EXPERIMENTAL
Intervention: Blocking the tibial and common peroneal nerves individually using ultrasound distal to sciatic bifurcation
Number of subjects: 76
Study 19996137 — intervention group
Group type: COMPARATOR
Intervention: Prebifurcation sciatic block
Number of subjects: 76
Study 18173309 — intervention group
Group type: COMPARATOR
Intervention: NAA/Cho ratio in patients with diffuse TBI within the first 10 days after injury (1.59 ± 0.46)
Number of subjects: 25
Study 18173309 — intervention group
Group type: COMPARATOR
Intervention: NAA/Cr ratio in patients with diffuse TBI within the first 10 days after injury (1.44 ± 0.21)
Number of subjects: 25
Study 18173309 — intervention group
Group type: EXPERIMENTAL
Intervention: NAA/Cho ratio minimum values in patients (1.05 ± 0.44)
Number of subjects: 25
Study 18173309 — intervention group
Group type: EXPERIMENTAL
Intervention: NAA/Cr ratio minimum values in patients (1.05 ± 0.30)
Number of subjects: 25
Study 18173309 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of NAA/Cho and NAA/Cr reductions with outcomes at 6 months
Number of subjects: 25
Study 18173309 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery of NAA/Cho levels at 40 days postinjury in patients with good outcomes
Number of subjects: 25
Study 16316872 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (200 to 1600 microg/d via Turbuhaler)
Number of subjects: 945
Study 16316872 — intervention group
Group type: COMPARATOR
Intervention: Triamcinolone acetonide (200 to 1600 microg/d via pressurized metered-dose inhaler)
Number of subjects: 945
Study 10481519 — intervention group
Group type: EXPERIMENTAL
Intervention: Deformities of rib chest wall
Number of subjects: 33
Study 8732323 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized decision support system (DSS) for lipid management
Number of subjects: 150000
Study 8732323 — intervention group
Group type: COMPARATOR
Intervention: Control group (baseline data collection)
Number of subjects: 150000
Study 1929311 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose ofloxacin (400 mg)
Number of subjects: 130
Study 1929311 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin (200 mg) once daily for 3 days
Number of subjects: 130
Study 1929311 — intervention group
Group type: COMPARATOR
Intervention: Trimethoprim-sulfamethoxazole (160:800 mg) twice daily for 7 days
Number of subjects: 130
Study 6357014 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (0.8 mg)
Number of subjects: 18
Study 6357014 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2 ml)
Number of subjects: 18
Study 6357014 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (1.5 ml/kg, p.o.)
Number of subjects: 18